Digital Content 
NEWS #PharmaBuzz
27 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/27/3033894/18362/en/Amarin-Marks-Key-Milestone-for-VASCEPA-VAZKEPA-Icosapent-Ethyl-Publication-of-Post-Hoc-Analysis-of-REDUCE-IT-in-Journal-of-the-American-Heart-Association-Reports-Benefit-on-Top-of-.html
25 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/25/3031955/18362/en/Amarin-Receives-National-Reimbursement-for-VAZKEPA-in-Austria.html
20 Nov 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218899
11 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/11/2978267/18362/en/Investigators-to-Present-New-REDUCE-IT-Subanalysis-of-VASCEPA-VAZKEPA-icosapent-ethyl-in-Patients-With-and-Without-Coronary-Artery-Disease-History-and-Mechanistic-Data-on-Eicosapen.html
09 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/09/2942721/18362/en/Research-Highlighting-the-Clinical-Impact-of-VASCEPA-VAZKEPA-icosapent-ethyl-in-Patients-with-Diabetes-and-High-Cardiovascular-Risk-and-the-Anti-Lp-a-Oxidation-Mechanistic-Effect-o.html
17 Jul 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/07/17/2914903/18362/en/Amarin-Receives-National-Reimbursement-for-VAZKEPA-icosapent-ethyl-in-Portugal.html
Share 